AQR Capital Management LLC Buys New Holdings in Definitive Healthcare Corp. (NASDAQ:DH)

AQR Capital Management LLC bought a new stake in Definitive Healthcare Corp. (NASDAQ:DH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 29,394 shares of the company’s stock, valued at approximately $155,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norden Group LLC bought a new stake in Definitive Healthcare during the 1st quarter worth approximately $83,000. Canada Pension Plan Investment Board bought a new stake in Definitive Healthcare during the 2nd quarter worth approximately $109,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Definitive Healthcare by 31.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock worth $116,000 after purchasing an additional 5,083 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Definitive Healthcare during the 1st quarter worth approximately $120,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Definitive Healthcare during the 2nd quarter worth approximately $127,000. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Stock Up 1.6 %

Shares of NASDAQ:DH opened at $4.54 on Friday. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.27. The stock’s 50-day moving average price is $4.36 and its 200-day moving average price is $5.36. The stock has a market capitalization of $535.42 million, a P/E ratio of -2.59, a price-to-earnings-growth ratio of 6.27 and a beta of 1.33. Definitive Healthcare Corp. has a 12-month low of $3.19 and a 12-month high of $10.62.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The company had revenue of $63.70 million during the quarter, compared to analyst estimates of $63.19 million. During the same period in the prior year, the business posted $0.08 earnings per share. Definitive Healthcare’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts anticipate that Definitive Healthcare Corp. will post 0.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DH shares. Deutsche Bank Aktiengesellschaft cut their target price on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. JPMorgan Chase & Co. downgraded Definitive Healthcare from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Wednesday, July 31st. Stifel Nicolaus decreased their price target on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Barclays decreased their price target on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.81.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.